Cargando…

Buparlisib is a brain penetrable pan-PI3K inhibitor

Characterization of the genomic landscapes of intracranial tumours has revealed a clear role for the PI3K-AKT-mTOR pathway in tumorigenesis and tumour maintenance of these malignancies, making phosphatidylinositol 3-kinase (PI3K) inhibition a promising therapeutic strategy for these tumours. Buparli...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Gooijer, Mark C., Zhang, Ping, Buil, Levi C. M., Çitirikkaya, Ceren H., Thota, Nishita, Beijnen, Jos H., van Tellingen, Olaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050274/ https://www.ncbi.nlm.nih.gov/pubmed/30018387 http://dx.doi.org/10.1038/s41598-018-29062-w

Ejemplares similares

ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost
por: de Gooijer, Mark C., et al.
Publicado: (2021)

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2()
por: de Gooijer, Mark C., et al.
Publicado: (2018)

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
por: Garrido-Castro, Ana C., et al.
Publicado: (2020)

Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
por: Bohnacker, Thomas, et al.
Publicado: (2017)

The G2 checkpoint—a node‐based molecular switch
por: de Gooijer, Mark C., et al.
Publicado: (2017)

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2014)

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer
por: Nixon, Mellissa J., et al.
Publicado: (2019)

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
por: Anderson, Jennifer L., et al.
Publicado: (2015)

Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
por: Netland, I. A., et al.
Publicado: (2016)

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
por: Younes, Anas, et al.
Publicado: (2017)

Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study
por: Piha-Paul, Sarina A., et al.
Publicado: (2019)

The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging
por: Wang, Shengfei, et al.
Publicado: (2019)

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

BCRP drives intrinsic chemoresistance in chemotherapy-naïve breast cancer brain metastasis
por: Uceda-Castro, Rebeca, et al.
Publicado: (2023)

A phase II study of buparlisib in relapsed or refractory thymomas
por: Abu Zaid, Mohammad I., et al.
Publicado: (2022)

BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
por: Speranza, Maria-Carmela, et al.
Publicado: (2016)

Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
por: Rewcastle, Gordon W, et al.
Publicado: (2017)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
por: Chen, I-Chun, et al.
Publicado: (2017)

Roles of PI3K pan-inhibitors and PI3K-δ inhibitors in allergic lung inflammation: a systematic review and meta-analysis
por: Kim, Jong Seung, et al.
Publicado: (2020)

Penetrating particle ANalyzer (PAN)
por: Wu, X., et al.
Publicado: (2019)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
Publicado: (2018)

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors
por: Choong, Meng Ling, et al.
Publicado: (2013)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

Modulation of Platelet Activation and Thrombus Formation Using a Pan-PI3K Inhibitor S14161
por: Yi, Wenxiu, et al.
Publicado: (2014)

The efficacy and safety of neoadjuvant buparlisib for breast cancer: A meta-analysis of randomized controlled studies
por: Luo, Qian, et al.
Publicado: (2019)

P659: BUPARLISIB A PROMISING THERAPEUTIC APPROACH IN CHRONIC MYELOID LEUKEMIA RESISTANT TO IMATINIB
por: Alves, Raquel, et al.
Publicado: (2023)

The Identification of Potent, Selective, and Brain Penetrant PI5P4Kγ Inhibitors as In Vivo-Ready Tool Molecules
por: Rooney, Timothy P. C., et al.
Publicado: (2022)

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
por: Bardia, Aditya, et al.
Publicado: (2019)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)

B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells
por: Zhou, Hongyu, et al.
Publicado: (2019)

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
por: Heffron, Timothy P., et al.
Publicado: (2016)

Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors
por: Morcos, Peter N., et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Protocol for live-cell imaging during Tumor Treating Fields treatment with Inovitro Live
por: Slangen, Paul L.G., et al.
Publicado: (2022)

PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors
por: Lonetti, Annalisa, et al.
Publicado: (2015)

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma
por: Koul, Dimpy, et al.
Publicado: (2017)

Penetration testing with Raspberry Pi
por: Muniz, Joseph, et al.
Publicado: (2015)

The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor
por: Tzeng, Huey-En, et al.
Publicado: (2015)

A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment
por: Csonka, Denes, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_49asonsmk1vq0q1utpq3ieio90